<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Ofatumumab is a unique monoclonal antibody that targets a distinct small loop <z:chebi fb="0" ids="53000">epitope</z:chebi> on the CD20 molecule </plain></SENT>
<SENT sid="1" pm="."><plain>Preclinical data show that ofatumumab is active against B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo>/<z:hpo ids='HP_0005550'>chronic lymphocytic leukemia</z:hpo> cells with low CD20-antigen density and high expression of complement inhibitory molecules </plain></SENT>
<SENT sid="2" pm="."><plain>In a phase 1/2 trial evaluating safety and efficacy of ofatumumab in relapsed or refractory follicular non-Hodgkin <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (FL) grade 1 or 2, 4 dose groups of 10 patients received 4 weekly infusions of 300, 500, 700, or 1000 mg </plain></SENT>
<SENT sid="3" pm="."><plain>Patients had a median of 2 prior FL therapies and 13% had elevated <z:chebi fb="4" ids="24996">lactate</z:chebi> dehydrogenase </plain></SENT>
<SENT sid="4" pm="."><plain>No safety concerns or maximum tolerated dose was identified </plain></SENT>
<SENT sid="5" pm="."><plain>A total of 274 adverse events were reported; 190 were judged related to ofatumumab, most occurring on the first infusion day with Common Terminology Criteria grade 1 or 2 </plain></SENT>
<SENT sid="6" pm="."><plain>Eight related events were grade 3 </plain></SENT>
<SENT sid="7" pm="."><plain>Treatment caused immediate and profound B-cell <z:mpath ids='MPATH_63'>depletion</z:mpath>, and 65% of patients reverted to negative BCL2 status </plain></SENT>
<SENT sid="8" pm="."><plain>Clinical response rates ranged from 20% to 63% </plain></SENT>
<SENT sid="9" pm="."><plain>Median time to progression for <z:hpo ids='HP_0000001'>all</z:hpo> patients/responders was 8.8/32.6 months, and median duration of response was 29.9 months at a median/maximum follow-up of 9.2/38.6 months </plain></SENT>
<SENT sid="10" pm="."><plain>Ofatumumab is currently being evaluated in patients with rituximab-refractory FL </plain></SENT>
<SENT sid="11" pm="."><plain>This trial was registered at www.clinicaltrials.gov as #NCT00092274 </plain></SENT>
</text></document>